Anti-Obesity Drugs Market: Global Strategic Business Report 2018 - High Drug Development Costs is a Major Setback - ResearchAndMarkets.com

The "Anti-Obesity Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2024.

This report analyzes the worldwide markets for Anti-Obesity Drugs in US$ Million.

The report profiles 25 companies including many key and niche players such as:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• GlaxoSmithKline PLC (UK)
• Eisai Co. Ltd. (Japan)
• Novo Nordisk A/S (Denmark)
• Rhythm Pharmaceuticals (USA)
• VIVUS Inc. (USA)

Key Topics Covered

1. Introduction, Methodology & Product Definitions

2. Industry Overview

3. Growth Drivers and Market Trends

• Alarming Rise in Global Obesity Levels - The Major Growth Factor
• Classification of BMI
• Exponential Increase in Urban Population
• Rising Incidence of Chronic Diseases Associated with Obesity Drive the Market Expansion
• Growing Middle Class Population to Drive the Market Growth
• Childhood Obesity - A Market with Unmet Needs
• Commercial Weight-Loss Companies Foray into the Market
• Online Drug Stores Boost Sales
• Barriers to Development of Effective Drugs
• Regulatory Additions - A Barrier to Entry?
• High Drug Development Costs - A Major Setback
• Weight Loss Alternatives - A Market Dampener

4. Select Research Initiatives

5. Obesity - An Introduction

6. Anti-Obesity Drugs - An Insight

7. Competitive Landscape

7.1 Focus on Select Global Players

7.2 Recent Industry Activity

8. Global Market Perspective

Total Companies Profiled: 25 The United States (9)

• Japan (2)
• Europe (8)
  • Germany (1)
  • The United Kingdom (1)
  • Italy (1)
  • Rest of Europe (5)
• Asia-Pacific (Excluding Japan) (6)

For more information about this report visit https://www.researchandmarkets.com/research/7pmxl6/antiobesity?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20180817005110/en/